Antigen Presentation Keeps Trending in Immunotherapy Resistance.

Antigen Presentation Keeps Trending in Immunotherapy Resistance.
复制标题

DOI：
10.1158/1078-0432.ccr-18-0698
复制
发表时间：
2018-07-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
通讯作者：
Ribas A
Ribas A
中科院分区：
其他
文献类型：
--
作者：
Kalbasi A;Ribas A
来源链接：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050090/

文献摘要

相似文献

通过功能获得性激酶组筛选，MEX 3B被鉴定为先前使用基于CRISPR的筛选未鉴定出的对T细胞免疫疗法的抗性的介体。MEX 3B是HLA-A的转录后调节因子，验证了肿瘤内在抗原呈递在T细胞免疫治疗中的关键作用，并指示了新的推定分子靶点。
Through a gain-of-function kinome screen, MEX3B was identified as a mediator of resistance to T cell immunotherapy not previously identified using CRISPR based screens. MEX3B is a post-transcriptional regulator of HLA-A, validating the critical role of tumor-intrinsic antigen presentation in T cell immunotherapy and indicating a new putative molecular target.